In the interview below, Useche provides an overview of Relevium’s two wholly owned subsidiaries: BGX E-Health (BGX) and Biocannabix Health (BCX). BGX offers a variety of dietary supplements, nutraceuticals, sports nutrition products and cosmeceuticals throughout the US and Europe. The products are distributed through large retailers like Walmart (NYSE:WMT) and Amazon (NASDAQ:AMZN).
BCX is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy. The company is currently integrating phytocannabinoids into its product offerings in Colombia. Relevium is also looking to offer these products in other countries in Latin America. To this aim, BCX intends to acquire Lifeline Pharma SAS, a late-stage applicant in Colombia, to cultivate, process and export phytocannabinoid extracts on a B2B basis in Latin America.
Useche also touches on Relevium’s Latin American strategy. The company intends to introduce its branded products online and through an extensive network of pharmacies in Colombia to create brand awareness before expanding into neighboring countries.
Useche said that some changes in legislation in the US, Canada and Latin America are needed to help companies realize their potential. He believes that branding rules should be changed in Canada and that federal legalization in the US would be beneficial.
Below is a transcript of our interview with Relevium CEO Aurelio Useche. It has been edited for clarity and brevity.
Investing News Network: Please tell us about Relevium and some of your recent developments.
Relevium CEO Aurelio Useche: Relevium is a vertically integrated health and wellness nutraceutical company integrating phytocannabinoids into its product offerings. We also have traditional over-the-counter formulations. We’re doing this by combining our cultivation and processing in Colombia, scientific research in Montreal and consumer packaged goods distribution in the US and Europe.
We operate under an acquisition and partnering model to offer a wide range of innovative health and wellness consumer products. Relevium operates through two wholly owned subsidiaries: BGX and BCX.
BGX is based in Orlando, Florida, and offers a variety of dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals under the Bioganix brand in the US and Europe. The brand is sold at some of the world’s largest retailers, including Walmart and Amazon.
Based in Montreal, Quebec, BCX is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy. The company is in the process of integrating the cultivation and processing of phytocannabinoids in Colombia to extend our product offering to Latin American countries.
INN: Could you tell us more about Lifeline Pharma?
AU: Lifeline Pharma is a late-stage applicant in Colombia for the cultivation, processing and export of phytocannabinoid extracts on a B2B basis. Once Lifeline is issued its first cultivation license, BCX intends to acquire the company. Lifeline is developing an initial 600,000 square foot cultivation facility, which is expected to be fully operational by February 2020. We plan to expand the facility in 2020 to 2.6 million square feet for a total production capacity of 170,000 kilograms of flower per year.
INN: How is Relevium positioning itself as a leader in the Latin American market?
AU: We plan to introduce some of our brands, like Bioganix, Pushpull and LeefyLyfe, to the Latin American marketplace in Colombia. We intend to sell our branded products online and through an extensive network of pharmacies in Colombia. Our initial objective is to secure brand recognition and obtain a trusted status before expanding to neighboring countries. We expect the production and export of high-end phytocannabinoid extracts to play a key role in positioning the company as a leading player in Latin America.
INN: What advancements in technology are most relevant to Relevium?
AU: In terms of medical phytocannabinoids, we’re focused on formulating unique medical products for niche applications. As for online marketing, the company intends to introduce a new geotagging technology that allows us to market directly to consumers through their mobile devices.
INN: What legislative advancements in the cannabis sector would be most beneficial for Relevium?
AU: We strongly believe in the deregulation of branding and sales channels in Canada. The US is ahead of Canada in terms of consumer packaged goods and the establishment of trusted brands. We’re also looking forward to cannabidiol and other non-psychoactive cannabinoids being listed as Generally Recognized as Safe by the US Food and Drug Administration. This will allow for the full integration of the benefits of phytocannabinoids into our existing formulations. As for Colombia, the deregulation of cannabis flower exports would enable us to take a leading role in providing global supply at a significantly lower cost.
This interview is sponsored by Relevium Technologies (TSXV:RLV,OTCQB:RLLVF,FWB:6BX). This interview provides information which was sourced by the Investing News Network (INN) and approved by Relevium Technologies in order to help investors learn more about the company. Relevium Technologies is a client of INN. The company’s campaign fees pay for INN to create and update this interview.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Relevium Technologies and seek advice from a qualified investment advisor.
This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.